MJ Greco, JE Kemnitzer, JD Fox, JK Choe, J Kohn, DJ Riley and GJ Poiani
Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, USA.

Inhibitors of collagen such as cis-4-hydroxy-L-proline (cHyp) may ameliorate bleomycin (bleo)-induced pulmonary fibrosis. An alternating polymer of poly(ethylene glycol) (PEG)-lysine (PEG-Lys) with cHyp attached as a pendant side chain was prepared for intratracheal delivery with bioinactive trans-Hyp (tHyp) polymer as control. To test whether the cHyp polymer has prolonged lung retention and sustained antifibrotic activity, we first instilled 3H- and 14C-labeled cHyp polymer in normal rats. Lung retention was 86 +/- 9% at 6 h and 29 +/- 3% at 7 d (n = 5). Next, rats were instilled intratracheally with either saline (sal) or 1.2 U bleo, and the following treatment groups were studied: Bleo/sal; Bleo/cHyp polymer; Bleo/tHyp polymer; and Bleo/PEG-Lys + cHyp. The dose of the test agents was 150 mg/kg polymer containing 8.5 mg/kg cHyp or tHyp instilled intratracheally at 7 and 14 d after bleo. At 21 d, hydroxyproline content (mg/lung) was: Control, 1.8 +/- 0.1; Bleo/sal 4.0 +/- 0.1*; Bleo/cHyp polymer, 2.8 +/- 0.3*+; Bleo/tHyp polymer, 4.4 +/- 0.2*; and Bleo/PEG-Lys + cHyp, 4.0 +/- 0.1* (*p < 0.05 versus Control; +p < 0.05 versus Bleo/sal; n = 5/group). The cHyp polymer also reduced lung total protein content, but the decrease was not significant. The dose required to produce 50% inhibition of lung collagen was approximately 700-fold less than monomeric cHyp. Thus, the cHyp polymer is a potent, long-acting antifibrotic agent which may be useful in treating lung fibrosis.

This article has been cited by other articles:

				Y. Ishii, S. Fujimoto, and T. Fukuda Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 550 - 556. [Abstract] [Full Text] [PDF]

				A. Gunther, N. Lubke, M. Ermert, R. T. Schermuly, N. Weissmann, A. Breithecker, P. Markart, C. Ruppert, K. Quanz, L. Ermert, et al. Prevention of Bleomycin-induced Lung Fibrosis by Aerosolization of Heparin or Urokinase in Rabbits Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1358 - 1365. [Abstract] [Full Text] [PDF]

				J. Cortijo, M. Cerda-Nicolas, A. Serrano, G. Bioque, J.M. Estrela, F. Santangelo, A. Esteras, A. Llombart-Bosch, and E.J. Morcillo Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats Eur. Respir. J., June 1, 2001; 17(6): 1228 - 1235. [Abstract] [Full Text] [PDF]

				H. L. HADDEN and C. A. HENKE Induction of Lung Fibroblast Apoptosis by Soluble Fibronectin Peptides Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1553 - 1560. [Abstract] [Full Text] [PDF]

				A. TAN, H. LEVREY, C. DAHM, V. A. POLUNOVSKY, J. RUBINS, and P. B. BITTERMAN Lovastatin Induces Fibroblast Apoptosis In Vitro and In Vivo . A Possible Therapy for Fibroproliferative Disorders Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 220 - 227. [Abstract] [Full Text]